Samsung BioLogics

Baxter International’s CDMO unit plans a $100 million expansion to its sterile fill-finish manufacturing facility in western Germany, the company announced last week. The investment adds to a multibillion-dollar investment spree among manufacturers worldwide.

In related news, Samsung Biologics has bought land in Incheon, South Korea, where it plans a $259 million genetic medicines facility, the Korea Herald reported in early November.

Samsung Biologics will expand its CDMO business with the construction of two new plants, South Korean media reported Wednesday, citing a company statement. Geared toward vaccines and cell and gene therapies, the new facilities at its Incheon hub are in addition to a previously announced “Super Plant” already under construction, according to FiercePharma.
The Wall Street Journal said the projects are part of a new, $205 billion investment spree across Samsung’s myriad businesses…

The state of the hunt:

The U.S. FDA approved Gilead’s Veklury (remdesivir) for hospitalized Covid-19 patients 12 and older.
  IAVI, Merck and Serum Institute of India will collaborate to develop anti-SARS-CoV-2 monoclonal antibodies they plan to make accessible to LMICs.
  AstraZeneca resumed U.S. Phase 3 trials of its AZD1222 Covid-19 vaccine candidate.



Phase 3 candidates:
J&J is “preparing to resume recruitment” for the…

Several contract development and manufacturing organizations announced this month that they are expanding operations to meet growing demand.

First, New Jersey-based Catalent announced last week that it is boosting softgel production capacity at its Buenos Aires facility for “high potency treatments in areas such as oncology” by the end of 2021.

Next, South Korea’s Samsung Biologics said it is investing approximately $2 billion in what it claims will be the world’s largest single-…

The state of the hunt: 

China’s CanSino is closing in on a vaccine, with its adenovirus viral vector-based Ad5-nCoV shot advancing to Phase 2, according to a disclosure filed yesterday. Gilead’s remdesivir remains a top contender among investigational therapies: the company has expanded its two Phase 3 trials of the drug from 1,000 to 4,000 enrollees. Hydroxychloroquine is now the subject of over 60 Covid-19 trials, according to



Contract biotech manufacturer Samsung BioLogics told Reuters on Tuesday that it believes it will raise as much as $2 billion this year to help fund new production capacity in what will be South Korea’s third largest initial public offering (IPO) valuing the company at more than $8 billion.

According to Reuters, Samsung BioLogics’ parent company, The Samsung Group, has been looking for new sources of growth outside its consumer electronics and construction businesses.

The Samsung…